"Fujirebio collaborates with Stanford Medicine to advance research and innovation in the field of infectious disease testing
Fujirebio, a leading innovator in in-vitro diagnostics, announced a collaboration with Stanford Medicine to advance research and innovation in the field of infectious disease testing. This collaboration aims to accelerate the adoption of ultrasensitive immunoassays that incorporate single-molecule counting technology developed by Fujirebio’s Silicon Valley wholly-owned subsidiary, Fluxus, Inc. Greater test sensitivity can better inform treatment decisions in the clinic, as well as accelerate studies towards therapeutics and preventive strategies against infectious disease threats worldwide.
• “Infectious diseases remain one of the greatest global health challenges of our time,” says Goki Ishikawa, President and CEO of Fujirebio Holdings, Inc.
• “By working with the Stanford Clinical Virology Laboratory under the direction of Professor Benjamin Pinsky and the Stanford Clinical Microbiology Laboratory under the direction of Professor Niaz Banaei, we are bringing together world-class scientific expertise, cutting-edge technology, and global health insights. This collaboration underscores our shared vision to create a healthier, more resilient world.”
• “This collaboration represents a significant step forward in our mission to improve public health globally, by combining Fujirebio’s global IVD expertise and Fluxus’ ultrasensitive detection systems with Stanford’s world-renowned research,” says Dr. Peter Wagner, president and CEO of Fluxus, Inc.
• “We are thrilled to be working with Stanford University’s prestigious infectious disease experts.”
Fujirebio, a member of H.U. Group Holdings Inc., is an R&D-driven company constantly developing new IVD testing technologies and unique biomarkers with high clinical value.
Fluxus is an industry leader and innovator in optofluidic technologies that develops ultrasensitive detection systems and assay solutions to advance the diagnosis, monitoring, and treatment of diseases.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!